Aldeyra Therapeutics (ALDX) Downgraded by ValuEngine

Aldeyra Therapeutics (NASDAQ:ALDX) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald set a $30.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 29th. Citigroup started coverage on shares of Aldeyra Therapeutics in a research note on Tuesday, December 4th. They issued a “buy” rating and a $23.00 price objective for the company. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 12th. Finally, BidaskClub upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 10th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aldeyra Therapeutics has an average rating of “Buy” and an average price target of $30.40.

Shares of NASDAQ:ALDX opened at $7.75 on Tuesday. Aldeyra Therapeutics has a 52 week low of $6.75 and a 52 week high of $16.70. The firm has a market capitalization of $203.66 million, a price-to-earnings ratio of -5.54 and a beta of 0.82. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.82 and a quick ratio of 4.82.

Several institutional investors have recently added to or reduced their stakes in the company. National Asset Management Inc. lifted its holdings in shares of Aldeyra Therapeutics by 14.3% in the 4th quarter. National Asset Management Inc. now owns 15,940 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 2,000 shares during the last quarter. American International Group Inc. lifted its holdings in Aldeyra Therapeutics by 23.4% during the 4th quarter. American International Group Inc. now owns 13,909 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 2,641 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in Aldeyra Therapeutics by 118.6% during the 4th quarter. Meeder Asset Management Inc. now owns 8,888 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 4,822 shares in the last quarter. Bank of America Corp DE lifted its holdings in Aldeyra Therapeutics by 139.4% during the 4th quarter. Bank of America Corp DE now owns 12,181 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 7,093 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Aldeyra Therapeutics by 66.6% during the 4th quarter. Rhumbline Advisers now owns 23,173 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 9,260 shares in the last quarter. Hedge funds and other institutional investors own 66.96% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Recommended Story: Bear Market – How and Why They Occur

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit